Showing results (81-90 of 586) with videos related to
Sort By:
Pageof 59
Nature Reviews. Drug Discovery|February 25, 2017
Accelerating development of scientific evidence for medical products within the existing US regulatory frameworkRachel E Sherman, Kathleen M Davies, Melissa A Robb, et al.The New England Journal of Medicine|March 12, 2015
Compliance with results reporting at ClinicalTrials.govMonique L Anderson, Karen Chiswell, Eric D Peterson, et al.American Heart Journal|March 27, 2007
Publication or presentation of results from multicenter clinical trials: evidence from an academic medical centerAslan T Turer, Kenneth W Mahaffey, Kate L Compton, et al.American Heart Journal|August 17, 2004
Slowing the progression of diabetic nephropathy and its cardiovascular consequencesPeter A McCullough, George L Bakris, William F Owen, et al.Expert Opinion on Investigational Drugs|May 22, 2008
Rivaroxaban, an oral direct factor Xa inhibitorJonathan P Piccini, Manesh R Patel, Kenneth W Mahaffey, et al.The American Journal of Medicine|January 13, 2004
Economic effects of beta-blocker therapy in patients with heart failurePatricia A Cowper, Elizabeth R DeLong, David J Whellan, et al.Journal of Interventional Cardiology|February 6, 2013
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?Peter B Berger, Judson B Williams, Vic Hasselblad, et al.JAMA Network Open|October 8, 2020
Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical TrialsFan Wang, Richard L Schilsky, David Page, et al.American Heart Journal|June 6, 2020
Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelinesAlexander C Fanaroff, Marat Fudim, Robert M Califf, et al.American Heart Journal|November 5, 2003
Evaluation of the dofetilide risk-management programNancy M Allen LaPointe, Anita Chen, Bradley Hammill, et al.Pageof 59